|
Oct 9
|
Corrections & Amplifications
|
|
Oct 9
|
PureTech Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis (IPF) and Use of a Bayesian Statistical Analysis for LYT-100 (Deupirfenidone) at CHEST 2024 Annual Meeting
|
|
Oct 1
|
PureTech to Present at CHEST 2024 Annual Meeting
|
|
Sep 30
|
FDA approves PureTech’s KarXT to treat schizophrenia in adults
|
|
Sep 27
|
PureTech-Invented KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults
|
|
Sep 6
|
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
|
|
Jul 23
|
PureTech Founded Entity Vedanta Biosciences Expands Leadership Team and Appoints Head of Commercial
|
|
Jun 24
|
PureTech Health: Completion of Tender Offer & Total Voting Rights
|
|
Jun 24
|
PureTech Health: Results of the Tender Offer
|
|
Jun 20
|
PureTech Announces Change of Board Role
|
|
Jun 18
|
PureTech Founded Entity Seaport Therapeutics Appoints Seasoned Executives to Management Team
|
|
Jun 13
|
PureTech Health: Results of Annual General Meeting
|
|
May 9
|
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
|
|
May 7
|
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
|
|
Mar 19
|
PureTech Proposes $100 Million Capital Return
|
|
Dec 22
|
PureTech Founded Entity Karuna Therapeutics to be Acquired by Bristol Myers Squibb for $14 Billion
|
|
Dec 20
|
PureTech Year End Update and Outlook for 2024
|
|
Dec 7
|
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023
|
|
Nov 29
|
PureTech Founded Entity Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia
|
|
Nov 14
|
PureTech's LYT-300 (Oral Allopregnanolone) Achieved Primary Endpoint in a Phase 2a Acute Anxiety Trial in Healthy Volunteers
|